Research Paper Volume 12, Issue 20 pp 20413—20431

Systemic analyses of expression patterns and clinical features for GIMAPs family members in lung adenocarcinoma

Sisi Deng1, , Zhi Zhang1, , Xiaoli Lu1, , Qi Zhou2, , Shilin Xia3,4, , Mi Li5, ,

  • 1 Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, P.R. China
  • 2 Institute (College) of Integrative Medicine, Dalian Medical University, Dalian 116044, P.R. China
  • 3 Clinical Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, P.R. China
  • 4 Department of Palliative Medicine, Graduate School of Medicine, Juntendo University, Tokyo 1138421, Japan
  • 5 Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, P.R. China

Received: April 29, 2020       Accepted: July 14, 2020       Published: October 28, 2020
How to Cite

Copyright: © 2020 Deng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


GTPase of immunity-associated proteins (GIMAPs) are frequently prescribed as important components of immune regulation complexes, which were known to play key roles in lung adenocarcinoma. However, little is known about the function of distinct GIMAPs in lung adenocarcinoma. To address this issue, this study investigated the biological function and pathway of GIMAPs in lung adenocarcinoma using multiple public databases. Absent expression of GIMAPs was found in lung adenocarcinoma at mRNA and protein levels. While a purity-corrected value uncovered that all GIMAPs were positively associated with the immune infiltration of lung adenocarcinoma. Furthermore, the expressions of GIMAPs were considered to be negatively associated with clinical cancer stages, patient’s gender and pathological tumor grades in patients with lung adenocarcinoma. Besides, higher mRNA expression of GIMAPs was significantly associated with longer overall survival of patients with lung adenocarcinoma. Taken together, these results may enable GIMAPs family members as diagnostic and survival biomarker candidates or even potential therapeutic targets for patients with lung adenocarcinoma.


GIMAPs: GTPase of immunity-associated proteins; LUAD: lung adenocarcinoma; CPTAC: Clinical Proteomic Tumor Analysis Consortium; WebGestalt: WEB-based Gene SeT AnaLysis Toolkit; TIMER: Tumor IMmune Estimation Resource.